On Wednesday, KeyBanc Capital Markets adjusted its stance on Certara Inc . (NASDAQ:CERT), a leading biosimulation company. The firm upgraded the stock from Sector Weight to Overweight and set a new price target of $23.00. This revision reflects KeyBanc's increased estimates and a stronger conviction in Certara's revenue trends, as well as its potential to meet the midpoint of its guidance range.
The upgrade comes amid positive indications from the biotech industry and improving market conditions for biosimulation, as noted by Certara's peers. KeyBanc's analysis suggests that Certara is well-positioned to benefit from these developments.
The new price target is based on the stock trading at approximately 8.5 times KeyBanc's fiscal year 2025 revenue estimate and around 24 times its fiscal year 2025 adjusted EBITDA estimate.
Certara's stock adjustment by KeyBanc indicates a positive outlook for the company's financial performance in the coming years. The firm's decision to upgrade the stock to Overweight signals confidence in Certara's ability to capitalize on favorable trends in the biotech sector and its end markets.
Investors may take note of KeyBanc's revised price target and outlook, which suggest a potential upside for Certara's shares. The target price of $23.00 represents an expectation for the company's value to increase based on projected revenue and earnings before interest, taxes, depreciation, and amortization (EBITDA).
Certara's focus on biosimulation, which is used for drug development, has positioned it as a key player in the biotechnology field. With the upgrade from KeyBanc, Certara's stock may attract additional attention from investors seeking to leverage the growth in the biotech industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.